Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

363
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
363
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

324
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
324
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

446
Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
446
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

600
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
600
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.5K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.5K
Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

533
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
533

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pioneers in Dermatology and Venereology: an Interview with Professor Beatrix Volc-Platzer.

Journal of the European Academy of Dermatology and Venereology : JEADV·2022
Same author

Fumaric acid esters for paediatric psoriasis.

The British journal of dermatology·2021
Same author

Successful treatment of Netherton syndrome with ustekinumab in a 15-year-old girl.

The British journal of dermatology·2020
Same author

Paraneoplastic Dermatomyositis: relevance of myositis-specific autoantibodies in a small cohort.

Journal of the European Academy of Dermatology and Venereology : JEADV·2019
Same author

Developing classification criteria for skin-predominant dermatomyositis: the Delphi process.

The British journal of dermatology·2019
Same author

Patch granuloma annulare: clinicopathological characteristics and response to phototherapy.

The British journal of dermatology·2019

Related Experiment Video

Updated: Apr 6, 2026

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy
10:55

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy

Published on: October 31, 2025

1.0K

[Dermatomyositis-update].

B Volc-Platzer1

  • 1Dermatologische Abteilung, Donauspital - Sozialmedizinisches Zentrum Ost Wien (Akademisches Lehrkrankenhaus der Medizinischen Universität Wien), Langobardenstrasse 122, 1220, Wien, Österreich, beatrix.volc-platzer@wienkav.at.

Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete
|July 30, 2015
PubMed
Summary
This summary is machine-generated.

Dermatomyositis is a rare inflammatory disease causing muscle weakness and a characteristic skin rash. Early diagnosis and treatment with corticosteroids, alongside new therapies, significantly improve patient prognosis.

More Related Videos

Quantitative Magnetic Resonance Imaging of Skeletal Muscle Disease
09:30

Quantitative Magnetic Resonance Imaging of Skeletal Muscle Disease

Published on: December 18, 2016

20.3K
Imaging CD4 T Cell Interstitial Migration in the Inflamed Dermis
11:28

Imaging CD4 T Cell Interstitial Migration in the Inflamed Dermis

Published on: March 25, 2016

11.4K

Related Experiment Videos

Last Updated: Apr 6, 2026

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy
10:55

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy

Published on: October 31, 2025

1.0K
Quantitative Magnetic Resonance Imaging of Skeletal Muscle Disease
09:30

Quantitative Magnetic Resonance Imaging of Skeletal Muscle Disease

Published on: December 18, 2016

20.3K
Imaging CD4 T Cell Interstitial Migration in the Inflamed Dermis
11:28

Imaging CD4 T Cell Interstitial Migration in the Inflamed Dermis

Published on: March 25, 2016

11.4K

Area of Science:

  • Rheumatology and Immunology
  • Dermatology
  • Neurology

Context:

  • Dermatomyositis is a rare idiopathic inflammatory myopathy affecting adults and children, predominantly females.
  • Key features include myositis with specific muscle pathology and a characteristic skin rash (heliotrope erythema, Gottron's sign/papules, nail fold changes).
  • Skin symptoms can precede muscle involvement by up to two years (amyopathic dermatomyositis).

Purpose:

  • To provide an overview of dermatomyositis, including its clinical manifestations, diagnostic considerations, and therapeutic strategies.
  • To highlight the role of new myositis-specific antibodies in understanding the disease's heterogeneity.
  • To discuss factors influencing prognosis, such as autoantibody profiles, disease subtypes, and comorbidities.

Summary:

  • Dermatomyositis presents with muscle inflammation and a distinctive rash; its pathogenesis involves immune cell activation and complement-mediated damage.
  • Treatment primarily involves oral corticosteroids, often combined with steroid-sparing agents like azathioprine, methotrexate, or intravenous immunoglobulins.
  • Emerging therapies include biologics (anti-CD20, anti-TNFalpha, anti-interferon) and Janus kinase inhibitors, currently under evaluation.

Impact:

  • The understanding of dermatomyositis has advanced, allowing for better clinicoserologic correlations and personalized treatment approaches.
  • Prognosis has significantly improved, with response rates to high-dose corticosteroids reaching 50-90%.
  • Ongoing research into novel therapies promises further improvements in managing this complex autoimmune condition.